Cambium Bio Limited

A$0.36As of Sun 8 Nov 2026, 12:00 UTC
ASX:CMBHealthcare
Country Australia
PE (Fwd) •••
TSR 3Y CAGR (27.12%)
Div yield —
ROE (194.37%)
Biotechnology
Beta (5Y) (0.41)
PE TTM —
TSR TTM (26.53%)
Mkt cap A$10.60M
ROIC (97.31%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.374
4.01%
(76.05%)
Hold 8|11|9|11|2
2Q26
3Q26
4Q26
1Q27
Earnings per share$
—
—
—
—
(0.92%)
8.28%
20.74%
15.45%
Revenue$M
0.930
0.969
1.020
1.069
9.32%
8.03%
8.70%
12.24%
Peers (US$7.277M)
Cap (US$)
PE
8.031M
—
7.761M
—
6.618M
—
Capital
TTM
5Y
10Y
Leveragex
1.637
0.129
0.151
EBIT/Intx
1.856
1.132
0.899
Own earn%
29.92
(132.64)
(121.17)
Sh yield%
38.60
29.30
29.34
Owners
Insiders/Inst%
7.32
48.26
Short interest%
5.10
SBC / revenue%
0.28
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
23–30
$1 testx
−12.3
Incr. ROIC%
7